Serum leptin concentrations in women taking oral contraceptives.
OBJECTIVE
To investigate serum leptin concentrations in women taking oral contraceptives containing the same gestagen and different doses of ethinyl estradiol.


METHODS
30 women received tablets containing 20 microg of ethinyl estradiol (EE) and 150 microg of desogestrel (DSG) (Mercilon) whereas another group of 30 women received 30 microg of EE and 150 microg of DSG (Marvelon). Serum leptin concentrations were estimated using a Leptin RIA kit (Linco Research USA) after an overnight fast on the first day of the cycle prior to the onset of therapy as well as after the 3rd and 6th treated cycles.


RESULTS
In both groups a positive correlation between serum leptin and body mass index (BMI) was found (r=0.56; P<0.001 and r=0.67; P<0.001). The initial serum leptin concentration in the Mercilon group was 7.62+/-8.46 ng/ml. This value was not statistically different from values after 3 months (9.31 8.23 ng/ml) and after 6 months (10.53+/-8.03 ng/ml) of treatment. Very similar results were found in patients receiving Marvelon: 8.81+/-6.56 ng/ml initially; 11.62+/-11.16 ng/ml at 3 months, and 10.38+/-7.32 ng/ml at 6 months. The statistical analysis did not reveal any significant difference at each investigated time point in either study group.


CONCLUSIONS
Modern low dose OC containing third generation gestagen and low dose of ethinyl estradiol, does not have any influence on serum leptin or BMI, and therefore does not exert a significant influence on body energy metabolism.
Rechberger
T
T
Department of Gynecological Surgery, University School of Medicine, Lublin, Poland. skorup@eskulap.am.lublin.pl
Baranowski
W
W
Postawski
K
K
Jakimiuk
A J
AJ
Tomaszewski
J
J
Kulik-Rechberger
B
B
Jakowicki
J A
JA
D000273:Adipose Tissue / Q000378:metabolism*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D017135:Desogestrel / Q000008:administration & dosage* / Q000009:adverse effects; D004734:Energy Metabolism / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D020738:Leptin; D011506:Proteins / Q000187:drug effects* / Q000378:metabolism
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D020738:Leptin; D011506:Proteins; D004997:Ethinyl Estradiol; D017135:Desogestrel